Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Targeting pro-inflammatory effector functions of islet macrophages using lipid nanoparticles to prevent diabetes
EF 2022-23
Résumé
Type 1 diabetes (T1D) is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells of the pancreas. Macrcophages are a type of immune cell - the garbage eaters of the body - that can be found in the pancreas in clusters of insulin-producing beta cells called pancreatic islets. Although these macrophages can help keep beta cells healthy, they may also cause inflammation in the pancreas which contributes to the loss of beta cells. This leads to less insulin production which causes blood sugar levels to rise in people with T1D. It may be possible, however, to increase the number of macrophages that help beta cells and decrease the amount that cause harm. Additionally, a group of proteins called the NLRP3 inflammasome is thought to be important in initiating inflammation in the panceatic islet and may therefore contribute to T1D development. We propose to either target the NLRP3 inflammasome in the pancreas with new therapies that will slow inflammation or maximize the number of islet macrophages that protect beta cells to prevent T1D. To do this, we will use lipid nanoparticles (LNPs) to deliver drugs to immune cells in the pancreas. LNPs are safe and effective for drug delivery, as has been demonstrated by the millions who have received safe and effective COVID-19 vaccines. These LNPs will deliver drugs that either target the NLRP3 inflammasome or increase the number of protective macrophages in the pancreas of rodent T1D models and determine if T1D onset is prevented by monitoring blood sugar levels. If successful, we will next determine whether these approaches can reverse established diabetes in mice and target human macrophages from pancreatic organ donors with diabetes as a step towards translation to clinical trials.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486117
Name
Ostromecki Courtney
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting pro-inflammatory effector functions of islet macrophages using lipid nanoparticles to prevent diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune; Diabetes; Inflammation; Macrophages; Nanomedicine; Nod Mice; Pancreatic Beta Cell
Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells of the pancreas. Macrcophages are a type of immune cell - the garbage eaters of the body - that can be found in the pancreas in clusters of insulin-producing beta cells called pancreatic islets. Although these macrophages can help keep beta cells healthy, they may also cause inflammation in the pancreas which contributes to the loss of beta cells. This leads to less insulin production which causes blood sugar levels to rise in people with T1D. It may be possible, however, to increase the number of macrophages that help beta cells and decrease the amount that cause harm. Additionally, a group of proteins called the NLRP3 inflammasome is thought to be important in initiating inflammation in the panceatic islet and may therefore contribute to T1D development. We propose to either target the NLRP3 inflammasome in the pancreas with new therapies that will slow inflammation or maximize the number of islet macrophages that protect beta cells to prevent T1D. To do this, we will use lipid nanoparticles (LNPs) to deliver drugs to immune cells in the pancreas. LNPs are safe and effective for drug delivery, as has been demonstrated by the millions who have received safe and effective COVID-19 vaccines. These LNPs will deliver drugs that either target the NLRP3 inflammasome or increase the number of protective macrophages in the pancreas of rodent T1D models and determine if T1D onset is prevented by monitoring blood sugar levels. If successful, we will next determine whether these approaches can reverse established diabetes in mice and target human macrophages from pancreatic organ donors with diabetes as a step towards translation to clinical trials.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ostromecki, Courtney
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~